Bemarituzumab is a first-in-class, humanized IgG1 моноклональный антитело against FGFR2b (a FGF рецептор). Bemarituzumab blocks fibroblast growth factors from связывание and activating FGFR2b. Bemarituzumab has the potential for cancer research.
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.